FDA
FDA seeks comments on combination product information collection
FDA opened a 60 day public comment opportunity covering information collection associated with product jurisdiction and combination product regulations.
Read the official sourceFDA
FDA corrects patent extension review period calculations
FDA corrected the stated regulatory review period lengths for ANDEMBRY, ANZUPGO, ANKTIVA, BIZENGRI, BRINSUPRI, and DAYVIGO. The underlying testing and approval phase dates remain unchanged.
Read the official sourceU.S. Congress
Clinical development bill referred to House committees
HR10857, which would amend federal law to advance next generation clinical development of novel treatments and cures, was referred to the House Energy and Commerce and Ways and Means committees.
Read the official sourceU.S. Congress
Generic drug access bill referred to House committees
The Protecting Consumer Access to Generic Drugs Act of 2026 was referred to the House Energy and Commerce and Judiciary committees.
Read the official sourceMHRA
MHRA publishes approved COVID-19 test product resource
MHRA provided guidance identifying COVID-19 test products that have been approved through test validation.
Read the official sourceWhy this matters
The FDA comment period gives stakeholders a formal channel to address information collection tied to product jurisdiction and combination products. The patent extension corrections warrant attention because the calculated review periods changed even though the underlying dates did not. The House bills remain at the committee referral stage, but they put clinical development and generic access on the legislative agenda. In the UK, the MHRA resource provides a direct reference for approved COVID-19 tests.
Scott Morvay
Founder, Gulfstream Intelligence
This brief provides general regulatory news and educational information. It is not legal or regulatory advice.